Clinical Trial Update: Empa PASS on Urinary Tract Malignancies

View source ↗

Summary

Completed post-authorization safety study (PASS) evaluating empagliflozin for urinary tract malignancies with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Renal Cell Carcinoma
• Urothelial Carcinoma

Drugs mentioned

• Jardiance (empagliflozin)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Diabetes Mellitus, Type 2 | Status: COMPLETED | Results posted: 2025-03-28